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cquired  partial  lipodystrophy  (Barraquer–Simons
yndrome) and  IgA  nephropathyipodistroﬁa  parcial  adquirida  (síndrome  de  Barraquer-Simons)
 nefropatía  IgA
ear Sir,
ipodystrophy syndromes are a heterogeneous group of rare
iseases characterised by selective loss of adipose tissue,
hich often leads to insulin resistance with a tendency to
evelop diabetes, dyslipidaemia, hepatic steatosis, acanthosis
igricans and hyperandrogenism.1 Acquired partial lipodys-
rophy (APL; OMIM:  608709), also known as Barraquer–Simons
yndrome, is one of the most common, and predominantly
ffects women (4:1). It is characterised by a progressive loss
f subcutaneous fat, usually starting in childhood,2 and pro-
resses from the head down, affecting the face, upper limbs,
runk and abdomen. Unlike other types of lipodystrophy,
nsulin resistance and metabolic complications, apart from
epatomegaly (60%), are rare.1,2
In 10–20% of cases, APL is associated with autoimmune
isorders, especially lupus. The most common complica-
ion (20%) is the development of membranoproliferative
lomerulonephritis type 2, or dense deposit disease (DDD)
pproximately 8 years after onset of the disease. The patho-
enesis of such renal involvement includes activation of
he alternative complement pathway (ACP).3 Patients show
ecreased serum C3 levels (70%) and are positive for C3NeF
80%),2 an autoantibody capable of altering the ACP and in the
ase of APL, it is suspected to play a role in the destruction of
atty tissue.4
We  had the case of a 15-year-old Caucasian girl with no rel-
vant family or personal clinical history who was diagnosed
f APL at the age of 5 due to progressive loss of subcutaneous
at from her face (Fig. 1a and b), with subsequent involve-
ent of neck and shoulders. In her regular visits, no clinical
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the slow progression of lipoatrophy and sustained decreased
serum levels of C3 (26–48 mg/dl; VN: 86–184). She had never
had clinical or analytical data suggestive of nephropathy,
dyslipidaemia, insulin resistance or hyperandrogenism. Her
serum leptin (8.03 ng/ml; NR: 15.3 ± 8.1 SD) and adiponectin
(8.3 mg/ml; NR: 12.0 ± 3.1 SD) levels were slightly low and the
DXA body composition study showed a reduction in total body
fat (17.7%; NR: 25.9 ± 6.3).
At the age of 13, after three days of fever and in the context
of acute gastroenteritis, she was found to have macroscopic
haematuria with non-nephrotic proteinuria (13 mg/kg/day)
and transient elevation of creatinine (maximum: 0.74 mg/dl).
The pyrexia subsided 24 h later, but the macroscopic haema-
turia persisted for two weeks, with no other symptoms and
with improvement in kidney function. Serum levels of IgA
were found to be high (377 mg/dl; NR: 40–350), C3 remained
low and C3NeF negative. Studies of autoimmunity (anti-
thyroid, anti-neutrophil and anti-nuclear antibodies) were
negative. Percutaneous kidney biopsy was performed one
month after the haematuria resolved. The specimen con-
tained 14 glomeruli and revealed the presence of focal and
segmental mesangial hypercellularity (Fig. 1c): M1,  E0, S0
and T0 according to the Oxford classiﬁcation5 (mesangial
hypercellularity [M], endocapillary proliferation [E], segmen-
tal glomerulosclerosis [S] and interstitial ﬁbrosis with tubular
atrophy [T]). Only one of the glomeruli had a crescent thatricio-López C, de Prada-Vicente I, Argente J. Lipodistroﬁa parcial
. 2016. http://dx.doi.org/10.1016/j.nefro.2016.03.003
occupied 26–50% of the glomerulus. Immunoﬂuorescence
showed granular mesangial IgA and C3 deposits (Fig. 1d). Elec-
tron microscopy conﬁrmed the presence of electron-dense
deposits in the glomerulus, ruling out DDD. The patient was
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Fig. 1 – (a and b) Progression of the loss of facial fat; (c) Glomeruli with increased mesangial cellularity, and focal and
lar im
r
2. Misra A, Peethambaram A, Garg A. Clinical features andsegmental involvement (H&E ×100) and (d) Mesangial granu
diagnosed with IgA nephropathy (IgAN), achieving clinical
remission with spontaneous disappearance of the proteinuria
and haematuria, but maintaining decreased serum levels of
C3 (33 mg/dl) and increased serum IgA (353 mg/dl).
APL is a rare disease of uncertain aetiology. The associa-
tion of APL with autoimmune diseases and DDD, in addition
to the decrease in C3 and C3NeF positivity point to an autoim-
mune basis2; although a possible genetic predisposition has
also been suggested.6 IgAN, meanwhile, is the most common
glomerular disease in the world.7 The aetiopathogenesis of
IgAN, which is not fully understood, also involves complement
activation through the ACP7–9 and sometimes through the
lectin pathway.10 Diagnosis is histological and kidney biopsy
shows mesangial immune deposits of IgA1 with C3 and occa-
sionally IgG or IgM. In the mesangial deposits, it is common to
ﬁnd components of the ACP (C3 and properdin), but not of the
classic pathway (C1q and C4) which, taken together with nor-
mal  serum C3 and other complement components, suggests
that the complement activation occurs in the kidney itself.
To summarise, we present the ﬁrst reported case of APL
associated to IgAN. Although, given the incidence of IgAN, it
could be a coincidence, the fact that the APL is often asso-
ciated with nephropathy, the DDD, whose pathogenesis, likemunoﬂuorescence with anti-IgA.
IgAN, involves activation of the ACP, raises the possibility of a
common link between the two diseases.
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